# DAWNZERA (AUTOINJECTOR) - (EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) ; Solution)

| | | | |
|---|---|---|---|
| **Generic Name** | DONIDALORSEN SODIUM | **Innovator** | IONIS PHARMS INC |
| **Dosage** | EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) ; Solution | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | None | **Known Para IV Filers** | None |
| **Other ANDA developers** | None | **Tentative Approvals** | None |
| **Final Approvals** | None | **Generic Launches** | None |
| **Indication** | DAWNZERA is a prekallikrein-directed antisense oligonucleotide indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.